secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001528287-23-000024
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace Q1 revenue $14.5M (+27% YoY) and raises FY2023 guidance to $52-54M
----------------------------------------------------------------------------

- Q1 revenue $14.5M, up 27% YoY and 13% sequentially; net loss narrowed to $10.4M from $11.5M.
- Full-year 2023 revenue guidance raised to $52-54M (prior $50-52M), implying 14-19% YoY growth.
- Gross margin 72% vs 73% YoY; operating expenses $18.7M; cash and investments $67.6M.
- RNS System utilization and DIXI Medical distribution drove growth; replacement implants declined.
- NAUTILUS pivotal study for primary generalized epilepsy enrolling as expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000152828723000024/0001528287-23-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000152828723000024/npce-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001528287-23-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer